Prot#MEK111759: An Open-Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias

Project: Research project

Project Details

StatusFinished
Effective start/end date3/11/113/11/17

Funding

  • PRA Health Sciences (MEK111759 // MEK111759)
  • GlaxoSmithKline LLC (MEK111759 // MEK111759)